ABSTRACT
INTRODUCTION
In aerobic organisms, ROS (reactive oxygen species) including O 2 -(anion), H 2 O 2 (hyderogen peroxide), hydroxyl radical ( . OH), and nitric oxide/ peroxynitrate (NO/ONOO -) are continually generated in cells via various endogenous and exogenouns sources such as mitochondrial electron transport chain, biotransformation of various xenobiotics and drugs, inflammation, UV and ionic irradiation and nitric oxide synthase. To detoxify ROS, mammalian cells have developed elaborate defense mechanisms. Oxidative stress occurs in the cells as a consequence of an imbalance between the prooxidant/antioxidant systems. Oxidative stress causes damage to cellular macromolecules such as nucleic acids, proteins, and lipids are particularly more damaging because the formation of lipid peroxidation products lead to a facile propagation of free radical reactions. Abstraction of a hydrogen atom form the polyunsaturated fatty acid moiety of membrane phospholipids initiates the process of lipid peroxidation (1).
Cisplatin is a potent antitumor drug. Cisplatin-based combination chemotherapy regimens are currently used as front-line therapy in the treatment of testicular cancer, ovarian germ cell tumors, epithelial ovarian cancer, head and neck cancer, advanced cervical cancer, bladder cancer, mesothelioma, endometrial cancer, non-small cell lung cancer, malignant melanoma, carcinoids, penile cancer, adrenocorticol carcinoma. The therapeutic effects of cisplatin are significantly improved by dose escalation. However, high-dose therapy with cisplatin is limited by its cumulative nephrotoxicity and neurotoxicity (2) .
It is well known that mitochondria continuously produce ROM (reactive oxygen metabolites) such as superoxide. Mitochondria also continuously scavenge ROM via the action of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, catalase and glutathione Stransferase. Cisplatin is known to accumulate in mitochondria of renal epithelial cells (3) . Several investigators have demonstrated that cisplatin induces ROS in renal epithelial cells primarily by decreasing the activity of antioxidant enzymes and by depleting intracellular concentrations of GSH (4, 5). A large number of studies have now accumulated documenting the beneficial effects of a variety of antioxidants in cisplatininduced nephrotoxicity. Agents such as superoxide dismutase, dimethylthiourea, and GSH have been shown to reduce the degree of renal failure and tubular cell damage when administered simultaneously with cisplatin in rats (6).
Carnosine is a biological dipeptide predominating in long lived tissues such as skeletal muscle and brain. Carnosine was shown protective effect on diabetes (7), antioxidant effect (pre and post consecutive doses of carnosine) on a single i.p. cisplatin-induced nephrotoxicity in mice (8) and curative effect on hypercholesterolemia-induced kidney insult (9) . Protective effects of carnosine supplement was also reported previously on chronic alchoholic and thioacetamide induced oxidative stress and hepatotoxicity (10) . Due to multifunctional properties of carnosine, the present study was designed to manipulate the effect of carnosine as potential antioxidant agent on cisplatin-induced lipid peroxidation and renal oxidative stress.
MATERIALS AND METHODS
24 Wistar albino rats of male sex (200-260g ) body weight, purchased from the animal house of ICCBS (International center for Chemical and Biological Sciences) Karachi, Pakistan for the study. Animals were acclimatized to the laboratory conditions one week before the start of experiment and caged in a quite temperature controlled room (23± 4°C). Rats had free access to water and standard rat diet. The experiments were conducted in accordance with ethical guidelines of internationally accepted principles for Laboratory use and care in animal research (Health research extension Act of1985).
The animals were divided into four experimental groups (n=6 After 48 hours of last dose of treated groups, animals were anesthetized, decapitated and blood was sampled from head wound in the lithium heparin coated tubes. A portion of blood was used to collect plasma. Kidneys were excised, trimmed of connective tissues, rinsed with saline to eliminate blood contamination, dried by blotting with filter paper and weighed. The tissues then kept in freezer -70°C until analysis.
Left kidneys were quickly removed, immerse in 10 % formalin, dehydrated and embedded in paraffin, sectioned at 3Pm, stained with hematoxylin and eosin (H&E) and evaluated by light microscopy.
Plasma samples were assayed for Urea & Creatinine. Plasma Urea was estimated by Diacetyl Monoxime Method (11) and Creatinine by Modified Jeff's Method (12) . Plasma sample was assayed for nitrate, MDA. Plasma Nitrate is estimated by ion selective electrode (ISE) method (Jenway 3345). Kidney homogenates were obtained using a tissue homogenizer Ultra Taurax T-25 Polytron at 4°C. The homogenates (1:10 w/v) were prepared by using a 100 mM KCl buffer (7:00 p H) containing EDTA 0.3 mM, All homogenates were centrifuged at 600 g for 60 minutes at 4°C and the supernatant was used for biochemical assays. 10µl of BHT (butylated hydroxytoluene) (0.5 M in acetonitrile) was added to prevent homogenate from oxidation and the homogenate was stored at -70°C until analysis for MDA and 4-HNE. The malonyldialdehyde (MDA) content, a measure of lipid peroxidation, was assayed in the form of thiobarbituric acid reacting substances (TBARS) by the method of Okhawa et al (13) and tissue 4-HNE content was measured by the method of Kinter et al (14) . Catalase activity was assayed by the method of Sinha et al (15) . Levels of SOD in the cell free supernatant were measured by the method of Kono et al (16) and GSH activity was determined by the procedure of Carlberg and Mannervik (17) .
Results are presented as mean± SE. Statistical significance and differences from control and test values were evaluated by Student's 't'-test. Statistical probability of P <0.01, P<0.05 were considered to be significant. Table I and Figure I shows effects of cisplatin, Carnosine and pretreatment of Carnosine with cisplatin on kidney & body weight respectively. A marked decrease in rats' body weight was observed in cisplatin-treated rats and CDDP + Carnosine. Alone Carnosine showed increase in body weight. The kidneys of rats treated with cisplatin were enlarged. Cisplatin-treated rats showed significantly increased kidney weight (P < 0.05) and relative kidney weight but result was not significant as compared to control. Alone Carnosine showed significantly increased relative kidney weight (P < 0.05). After 5 alternate days cisplatin-treated rats showed glomeruli congestion, marked ATN in proximal and distal tubule, decrease in the height of epithelial cells, shedding of atypical cytoplasm and loss of brush boarder (Fig II B) . Lumen wide opens and marked congestion in vessels (++++) were also seen. Pretreatment with carnosine markedly prevented congestion in glomeruli and vessels (+) and other alterations (Fig. II D) . Alone carnosine had showed no alterations (Fig II C) .
RESULTS
Cisplatin treated rats showed a markedly increased level of plasma urea (76.45 ± 7.41, P<0.01) as compared to control (Table II) . Alone Carnosine showed slightly increased urea level but the results were not significant. Results were not different in CDDP+Carnosine group as compared to control showing correction of urea level. Table II shows a significant effect on plasma creatinine level in cisplatin and pretreatment with Carnosine. Creatinine level was significantly increased (11.85 ± 1.56, P < 0.01) in cisplatin treated rats as compared to control. Pretreatment with Carnosine partially prevented increase in plasma creatinine level in CDDP+Carnosine group.
Carnosine Alone group showed slightly increased creatinine level (5.45±1.19, P<0.01) as compared to control.
Increased level of plasma MDA was observed in cisplatintreated rats (19.26±0.71, P<0.05). A significant decreased in plasma MDA was noted after Carnosine alone (7.28 ±1.53, P<0.01). The MDA level was also decreased in CDDP+Carnosine pretreated rats but results were not significant (Table II) . Values are mean±SE; Significant difference between control, cisplatin, c.intybus extract and c.intybus extract +cisplatin treated rats by t-test **P<0.05 (Table II) in cisplatin treated rats, indicating nitrosative stress. CDDP+Carnosine group showed no change as compared to control. Carnosine Alone treatment showed no significant result. Tissue catalase level decreased significantly (0.25 ± 0.025, P < 0.01) in cisplatin treated group as compared to control (Table II ). Carnosine prevented decreased catalase level in CDDP+Carnosine group. While Carnosine alone showed no significant effect. Table II shows a significant effect of cisplatin treated (19.83 ± 2.67, P < 0.01) rats. Cisplatin treatment decreased the SOD level significantly. In CDDP+Carnosine group the SOD level was restored. Carnosine alone showed no significant effects. Table II shows a significant decreased in GSH level in cisplatintreated rats (1.50 ± 0.66, P<0.01) as compared to control. A decrease was partially prevented by carnosine in CDDP+Carnosine group. Carnosine alone showed a slight decreased GSH level (2.63 ± 0.38, P<0.01) as compared to control group.
DISCUSSION
Using an experimental model of CDDP-induced nephrotoxicity in rats, we evaluated the renal activity of the key antioxidant enzymes (GSH, SOD, Catalase), the lipid peroxides (LPOs) MDA, 4-HNE content of tissue as an index of lipid peroxidation.
In the present study, the rats treated with cisplatin showed a decrease in body weight (Fig I) . Mora et al suggested that CDDP-induced weights loss might be due to gastrointestinal toxicity and by reduced ingestion of food. Our results demonstrated that repeated treatment with CDDP (3mg/ kg) for 5 alternate days induced biochemical and histological signs of renal injury (Fig II ) with significant reduction in the activity of Catalase, SOD and GSH (Table II) .
The impairment of kidney function by cisplatin is recognised as the main side effect and the most important dose-limiting factor associated with its clinical use. Several investigators (18) reported that the alterations induced by cisplatin in the kidney functions were characterized by signs of injury such as increase of products of LPO (lipid peroxide) and changes in GSH levels in kidney tissue, creatinine and urea levels in plasma. The present study showed that administration of cispaltin to rats caused a reduction in glomerular filtration rate, which correlated with increased creatinine and urea in plasma (Table II) . The alterations in glomerular function in cisplatintreated rats may also be secondary to ROS (reactive oxygen species) (19) which induce mesangial cells contraction, altering the filtration surface area and modifying the ultrafiltration coefficient factors that decrease the glomerular filtration rate (10).
The impairment in kidney function was accompanied by an increased MDA contents in kidney tissue (3, 19) . Our results are also in accordance with previous studies as shown in (Table II) . These biochemical parameters were well correlated with the renal histological results. Although the exact mechanism of CDDP-induced nephrotoxicity is not well understood, several investigators have shown that CDDP nephrotoxicity is associated with LPO in renal tissue. LPO is ascribed to a free radical-mediated chain reaction that damages cell membranes (20) and inhibition of this process by carnosine is mainly attributed to the ability of scavenger of free radicals. It uniquely present double antioxidant action, Values are mean ± SE; Significant difference between control, cisplatin, carnosine and carnosine +cisplatin treated rats by t-test **P<0.05, *P<0.01
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scavenging ROS, preventing lipid peroxidation of cell membranes, and regaining those already oxidized (10) . Carnosine Alone showed significantly decreased MDA level in plasma and tissue as compared to control. It is suggested that exogenously injected carnosine may be responsible for decreased MDA levels in carnosine alone -treated rats (Table  II) . It is known that carnosine is an endogenously synthesized dipeptide which is present in brain, cardiac muscle, kidney, stomach, olfactory bulbs and in large amounts in skeletal muscle (21) . It is reported previously that 4-HNE , the major D,E unsaturated aldehyde formed by the degradation of both Z 3 and Z 6 poly unsaturated fatty acid during lipidperoxidation is fairly stable and present in relatively higher amounts in biological membranes under the conditions of oxidative stress (1) .
Several studies demonstrated that CDDP-induced acute nephrotoxicity is mediated by depletion of renal GSH and by impaired activity of SOD and glutathione as well as an increase in renal lipid peroxidation (19, 22, 23, 24) . The role of NO and RNS in cisplatin-induced nephrotoxicity has not been completely established. It has been shown that the renal content of nitrate/nitrite is increased in cisplatin-treated rats suggesting that NO is increased in these animals (25, 26) . The increase in renal ONOO -induced by cisplatin may be secondary to the increase in NO and O 2 production (Table II) . In fact, there are evidences of the renal increase in NO production in cisplatin nephrotoxicity (27) . The O 2 •-increase in cisplatin-nephrotoxicity may be simply consequence of the mitochondrial dysfunction (4) and the decrease in superoxide dismutase activity (28) . One of the most important intracellular antioxidant systems is the glutathione redox cycle. GSH is one of the essential compounds for maintaining cell integrity because of its reducing properties and participation in the cell metabolism. The depletion in the renal GSH level has been observed in rats in response to oxidative stress caused by CDDP treatment (29) . It has been suggested that cisplatin is able to generate reactive oxygen species, and that is also inhibits the activity of antioxidant enzymes in renal tissue such as CAT, SOD, GSH-Px (30, 18) . The antioxidant property of carnosine is important manifestation as it directly interacts with lipid peroxidation products (30) . Taking into account the biochemical parameters and histological findings it is suggested that increased level of 4-HNE and MDA in cisplatintreated rats are responsible for renal oxidative stress. Pretreatment of carnosine significantly reduced the lipid peroxides and restored endogenous antioxidant enzymes. Carnosine is naturally occurring dipeptide, subsequent doses may interfere with the normal biological functions. Dose adjustment should be monitored carefully to manipulate the oxidant/antioxidant status. The present results and previous findings show that increased lipid peroxides implicate the renal oxidative stress. Moreover, combined therapy of carnosine with cisplatin successively attenuates the antioxidant system.
